Initial clinical results from OTC-HOPE, the first in vivo, liver directed, AAV-mediated gene insertion study in neonatal OTC deficiency: complete clinical response observed in first male infant to receive ECUR-506 and complete 24-week Phase 1/2 study (852)
https://iecure.com/wp-content/uploads/ASGCT_poster_iECURE_852.pdf